Posterior Segment Eye Disorders Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 32.12 Billion |
| Market Size (2029) | USD 41.82 Billion |
| CAGR (2024 - 2029) | 5.42 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Posterior Segment Eye Disorders Market Analysis
The Posterior Segment Eye Disorders Market size is estimated at USD 32.12 billion in 2024, and is expected to reach USD 41.82 billion by 2029, growing at a CAGR of 5.42% during the forecast period (2024-2029).
The COVID-19 pandemic disrupted the research and development activities of other therapies and drugs for medical conditions other than COVID-19. It impacted the treatment procedures and supply chains of pharmaceuticals and medical devices worldwide and the market for posterior segment eye disorders. For instance, according to a health article published in March 2021 by Oftalmologàa Barraquer, COVID-19 caused severe and irreversible consequences for people with glaucoma who suffered a very rapid evolution of the disease and have not been able to carry out follow-ups by the specialist, which, in some cases, resulted in a loss of the visual field. Therefore, the overall impact of COVID-19 on the posterior segment eye disorders market was adverse, primarily due to the decline in the diagnostics and treatment procedures of the diseases associated with the posterior segment of the eye. However, the rise in eye disorder surgeries worldwide to clear the backlogs of surgical procedures caused by the pandemic-related restrictions compensated for the market's growth in the later phase of the pandemic.
Posterior segment eye disorders are one of the major causes of visual impairments worldwide. Their prevalence is increasing gradually due to the increase in the prevalence of eye diseases, diabetes, and geriatric populations that are more vulnerable to eye ailments. With the increase in the burden of these diseases, the demand for diagnostics and treatment is increasing worldwide, driving the growth of the studied market.
According to the World Glaucoma Association (WGA) 2022 update, around 79.6 million people were living with glaucoma in 2020, and the number is projected to reach 111.8 million people by 2040. It also highlighted that at least 50% of glaucoma sufferers are unaware of their condition, and around 90% of glaucoma cases in some developing countries are undetected. Thus, the surge in glaucoma is ultimately projected to boost the posterior segment eye disorders market over the forecast period.
With the launch of new products, research and development, collaboration, mergers, and acquisitions, the market for posterior segment eye disorders is expected to grow during the forecast period. For instance, in June 2022, Iridex Corporation received regulatory approval to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases in China from its National Medical Products Administration (NMPA).
Due to the rising awareness about eye disorders and the factors mentioned above, the posterior segment eye disorders market is expected to register healthy growth over the forecast period. However, factors such as stringent regulatory policies of different countries and the lack of proper healthcare infrastructure in developing and under-developing countries are likely to restrain this growth.
Posterior Segment Eye Disorders Market Trends
Small Molecules by Drugs Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Compounds with a low molecular weight that can change the biochemical processes for treating diseases are known as small-molecule drugs. Factors such as the growing burden of eye disorders, increasing R&D for the innovation of new therapeutics, and the launch of products are driving segmental growth.
As per the study published in November 2021 by the National Library of Medicine, around 103.12 million adults were living with diabetic retinopathy globally in 2020, and the number is projected to increase to 160.50 million by 2045. Thus, the growing burden of eye disorders is likely to increase the demand for their treatment, thus driving the segment.
The market segment is also boosted by increasing clinical studies and collaboration among the market players. For instance, in December 2021, AbbVie Inc. (Allergan) received approval for VUITY (pilocarpine HCl ophthalmic solution) 1.25% by the US FDA to treat presbyopia and be available by prescription in pharmacies in the United States. Such launches are expected to drive the growth of the market segment. Thus, the small molecules segment is expected to project growth over the forecast period.
North America is Expected to Hold a Major Market Share Over the Forecast Period
North America is anticipated to have significant market growth owing to its well-established healthcare infrastructure, the presence of key market players, new product launches, and the rising burden of posterior eye disorders in the region.
The growing mergers and acquisitions are one of the key reasons for the market's growth. For instance, in November 2021, Alcon acquired Ivantis Inc. to expand its product portfolio by adding the Hydrus micro stent for surgical glaucoma. Hydrus micro stent is one of the key products in Canada. With this acquisition, Alcon expanded its presence in the market.
In September 2021, Zilia Inc. received USD 3.16 million through seed financing. This would aid the company's entry into ocular diagnostics by increasing the number of posterior segment eye disorders diagnoses. The product can measure oxygen saturation in the eye, an important biomarker for eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration.
Hence, owing to such factors, the North American market is expected to have faster growth over the forecast period.
Posterior Segment Eye Disorders Industry Overview
The market for posterior segment eye disorders is moderately fragmented. Market players are focusing on new product launches, product innovation, regional expansions, and collaborations to increase their market share. The key market players operating in the market include F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals Inc., Rainbow Medical Ltd (Nano Retina), Second Sight Medical, and Merck & Co. Inc.
Posterior Segment Eye Disorders Market Leaders
-
F. Hoffmann-La Roche AG
-
Regeneron Pharmaceuticals, Inc.
-
Rainbow Medical Ltd. (Nano Retina)
-
Second Sight Medical
-
Merck & Co., Inc.
*Disclaimer: Major Players sorted in no particular order
Posterior Segment Eye Disorders Market News
- In June 2022, Amring Pharmaceuticals Inc. (Amring) received the US FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic in Ocudose).
- In April 2022, Sandoz launched a generic combination of eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie's COMBIGAN in the United States to lower eye pressure in patients with ocular hypertension (high eye pressure).
Posterior Segment Eye Disorders Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Back of the Eye Disorders
4.2.2 Growing R&D for New Therapies for the Treatment of Posterior Segment Eye Disorders
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Drugs
5.1.1.1 Small Molecules
5.1.1.2 Biologics
5.1.2 Devices
5.1.2.1 Therapeutic Devices
5.1.2.2 Diagnostic Devices
5.2 By Application
5.2.1 Macular Degeneration
5.2.2 Glaucoma
5.2.3 Diabetic Retinopathy
5.2.4 Other Applications
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alcon Inc.
6.1.2 Abbvie Inc. (Allergen PLC)
6.1.3 Bausch Health Companies Inc.
6.1.4 F Hoffmann-La Roche
6.1.5 Merck & Co. Inc.
6.1.6 Novartis AG
6.1.7 Santen Pharmaceuticals
6.1.8 Rainbow Medical Ltd (Nano Retina)
6.1.9 Regeneron Pharmaceuticals Inc.
6.1.10 Second Sight Medical Products Inc.
6.1.11 Aerie Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Posterior Segment Eye Disorders Industry Segmentation
As per the scope of the report, posterior segment eye disorders are also known as the retina, optic nerve, and choroid diseases. The primary disorders include glaucoma, diabetic retinopathy, macular degradation, and others. The report covers the drugs and devices that are used in the diagnosis and treatment of back-eye diseases.
The posterior segment eye disorders market is segmented by product (drugs and devices (therapeutic devices and diagnostic devices), application (macular degeneration, glaucoma, diabetic retinopathy, other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.
| By Product | ||||
| ||||
|
| By Application | |
| Macular Degeneration | |
| Glaucoma | |
| Diabetic Retinopathy | |
| Other Applications |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Posterior Segment Eye Disorders Market Research FAQs
How big is the Posterior Segment Eye Disorders Market?
The Posterior Segment Eye Disorders Market size is expected to reach USD 32.12 billion in 2024 and grow at a CAGR of 5.42% to reach USD 41.82 billion by 2029.
What is the current Posterior Segment Eye Disorders Market size?
In 2024, the Posterior Segment Eye Disorders Market size is expected to reach USD 32.12 billion.
Who are the key players in Posterior Segment Eye Disorders Market?
F. Hoffmann-La Roche AG , Regeneron Pharmaceuticals, Inc. , Rainbow Medical Ltd. (Nano Retina), Second Sight Medical and Merck & Co., Inc. are the major companies operating in the Posterior Segment Eye Disorders Market.
Which is the fastest growing region in Posterior Segment Eye Disorders Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Posterior Segment Eye Disorders Market?
In 2024, the North America accounts for the largest market share in Posterior Segment Eye Disorders Market.
What years does this Posterior Segment Eye Disorders Market cover, and what was the market size in 2023?
In 2023, the Posterior Segment Eye Disorders Market size was estimated at USD 30.47 billion. The report covers the Posterior Segment Eye Disorders Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Posterior Segment Eye Disorders Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Posterior Segment Eye Disorders Industry Report
Statistics for the 2024 Posterior Segment Eye Disorders market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Posterior Segment Eye Disorders analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
